This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Elanco, Bayer animal health deal clears informal New Zealand review

By Laurel Henning ( July 9, 2020, 03:14 GMT | Insight) -- US-based Elanco Animal Health’s plan to acquire German pharmaceutical company Bayer’s animal-health business in a $7.6 billion deal has cleared a regulatory hurdle in New Zealand after the country’s competition watchdog said the deal would not substantially lessen competition. In announcing the conclusion of its informal merger review, the New Zealand Commerce Commission said the clearance was conditional on Elanco's divestment of three brands: Maggo, Zapp Encore, and Osurnia.US-based Elanco Animal Health’s plan to acquire German pharmaceutical company Bayer’s animal-health business in a $7.6 billion deal has cleared a regulatory hurdle in New Zealand after the country’s competition watchdog said the deal would not substantially lessen competition....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login